LINC00687: A Potential Drug Target for Alzheimer's Disease (G728450)

Target Name: LINC00687

NCBI ID: G728450

LINC00687

Other Name(s): dJ1012F16.1 | long intergenic non-protein coding RNA 687 | Long intergenic non-protein coding RNA 687 | C20orf61

LINC00687: A Potential Drug Target for Alzheimer's Disease

LINC00687 (dJ1012F16.1) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) in the field of neurodegenerative diseases, specifically Alzheimer's disease. The RNA molecule is derived from the genomic region of chromosome 10 on position d1012 of chromosome 12, and its full-length transcript has a length of 219 nucleotides.

LINC00687 is a small non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. It is expressed in a variety of tissues and cells in the body, including brain, spleen, and heart, and its levels have been shown to be affected by a variety of cellular and environmental factors.

One of the most promising aspects of LINC00687 is its potential as a drug target. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells, leading to a range of symptoms and cognitive impairments. There is currently no cure for Alzheimer's disease, and the development of new drugs to treat the disease is a major area of research.

LINC00687 has been shown to be involved in the regulation of the production of amyloid peptides, which are thought to contribute to the development of Alzheimer's disease. Amyloid peptides are derived from the abnormal aggregation of the protein beta-amyloid, which is a hallmark of Alzheimer's disease. The accumulation of beta-amyloid in the brain is thought to contribute to the development of neurodegeneration and the progression of the disease.

In addition to its role in the regulation of beta-amyloid production, LINC00687 has also been shown to be involved in the regulation of the production of neurotransmitters, such as dopamine and serotonin. These neurotransmitters are important for the functioning of various brain regions and are thought to be involved in the progression of Alzheimer's disease.

The expression of LINC00687 has been shown to be regulated by a variety of factors, including the expression of genes that encode its precursor protein, the levels of certain enzymes involved in its synthesis and degradation, and the presence of certain proteins that interact with it.

While further research is needed to fully understand the role of LINC00687 in the development and progression of Alzheimer's disease, its potential as a drug target is an exciting area of research. If LINC00687 is found to be an effective drug target, it could lead to the development of new treatments for this debilitating and progressive disease.

Protein Name: Long Intergenic Non-protein Coding RNA 687

The "LINC00687 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00687 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets